Authors: Alice Weatherston
In general, less than 50% of children with high risk neuroblastoma survive for longer than 5 years following a diagnosis. However, the results of a Phase III trial presented this week at the American Society of Clinical Oncology Annual Meeting (3–7th June 2016, IL, USA) has indicated that the addition of a second autologous stem cell transplant (ASCT), utilizing the patient’s own stem cells, could improve survival outcomes.
Children with a median age of 3.1 years that had been newly diagnosed with high-risk neuroblastoma were enrolled onto the trial. Of the patients, 88% had Stage 4 disease and 38.2% had a tumor with MYCN amplification, a high risk genetic abnormality.